Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Cardiotoxicity of doxorubicin (DOX) remains an important health concern. DOX cardiotoxicity is cumulative-dose-dependent and begins with the first dose of chemotherapy. No biomarker for presymptomatic detection of DOX cardiotoxicity has been validated. Our hypothesis is that peripheral blood cells (...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-08, Vol.11 (8), p.e0160224
Main Authors: Todorova, Valentina K, Makhoul, Issam, Siegel, Eric R, Wei, Jeanne, Stone, Annjanette, Carter, Weleetka, Beggs, Marjorie L, Owen, Aaron, Klimberg, V Suzanne
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibiotics, Antineoplastic - therapeutic use
Antibiotics, Antineoplastic - toxicity
Apoptosis
Arthritis
Asthma
Biological markers
Biology and Life Sciences
Biomarkers
Biomarkers - blood
Blood cells
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer
Cardiotoxicity
Cardiovascular research
Chemotherapy
Complications and side effects
Doxorubicin
Doxorubicin - adverse effects
Doxorubicin - therapeutic use
Doxorubicin - toxicity
Drug therapy
Female
Functional analysis
Gene expression
Granulocytes
Health aspects
Heart
Heart - drug effects
Heart diseases
Heart failure
Humans
Identification and classification
Inflammation
Inflammatory response
Kidney diseases
Laboratories
Leukocytes (neutrophilic)
Leukocytes, Mononuclear - cytology
Leukocytes, Mononuclear - drug effects
Leukocytes, Mononuclear - metabolism
Lupus
Measurement
Medicine and Health Sciences
Middle Aged
Myocardium - metabolism
Neutrophils
Oncology
Patients
Peripheral blood
Proteins
R&D
Research & development
Studies
Surgery
Toxicity
Transcriptome
Ventricular Function, Left - drug effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiotoxicity of doxorubicin (DOX) remains an important health concern. DOX cardiotoxicity is cumulative-dose-dependent and begins with the first dose of chemotherapy. No biomarker for presymptomatic detection of DOX cardiotoxicity has been validated. Our hypothesis is that peripheral blood cells (PBC) gene expression induced by the early doses of DOX-based chemotherapy could identify potential biomarkers for presymptomatic cardiotoxicity in cancer patients. PBC gene expression of 33 breast cancer patients was conducted before and after the first cycle of DOX-based chemotherapy. Cardiac function was evaluated before the start of chemotherapy and at its completion. Differentially expressed genes (DEG) of patients who developed DOX-associated cardiotoxicity after the completion of chemotherapy were compared with DEG of patients who did not. Ingenuity database was used for functional analysis of DEG. Sixty-sevens DEG (P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0160224